- Abstract:
-
Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romos...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Publisher:
- American Association for the Advancement of Science Publisher's website
- Journal:
- Science Translational Medicine Journal website
- Volume:
- 12
- Issue:
- 549
- Article number:
- eaay6570
- Publication date:
- 2020-06-24
- Acceptance date:
- 2020-05-26
- DOI:
- EISSN:
-
1946-6242
- ISSN:
-
1946-6234
- Pubs id:
-
1112307
- Local pid:
- pubs:1112307
- Language:
- English
- Keywords:
- Copyright holder:
- Bovijn et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
- Notes:
- This is the accepted manuscript version of the article. The final version is available from American Association for the Advancement of Science at: https://doi.org/10.1126/scitranslmed.aay6570
Journal article
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record